|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ABHD17C |
Gene summary for ABHD17C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ABHD17C | Gene ID | 58489 |
| Gene name | abhydrolase domain containing 17C, depalmitoylase | |
| Gene Alias | FAM108C1 | |
| Cytomap | 15q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0002084 | UniProtAcc | Q6PCB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58489 | ABHD17C | CCI_1 | Human | Cervix | CC | 2.28e-05 | 9.25e-01 | 0.528 |
| 58489 | ABHD17C | CCI_2 | Human | Cervix | CC | 8.72e-19 | 1.61e+00 | 0.5249 |
| 58489 | ABHD17C | CCI_3 | Human | Cervix | CC | 7.86e-06 | 5.67e-01 | 0.516 |
| 58489 | ABHD17C | Tumor | Human | Cervix | CC | 1.04e-04 | 1.98e-01 | 0.1241 |
| 58489 | ABHD17C | sample3 | Human | Cervix | CC | 8.80e-16 | 3.82e-01 | 0.1387 |
| 58489 | ABHD17C | H2 | Human | Cervix | HSIL_HPV | 5.17e-05 | 2.89e-01 | 0.0632 |
| 58489 | ABHD17C | T3 | Human | Cervix | CC | 4.48e-11 | 4.02e-01 | 0.1389 |
| 58489 | ABHD17C | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.14e-09 | -4.66e-01 | 0.0155 |
| 58489 | ABHD17C | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.26e-06 | -3.59e-01 | 0.3005 |
| 58489 | ABHD17C | A015-C-203 | Human | Colorectum | FAP | 2.01e-19 | -4.44e-01 | -0.1294 |
| 58489 | ABHD17C | A015-C-204 | Human | Colorectum | FAP | 8.44e-04 | -3.14e-01 | -0.0228 |
| 58489 | ABHD17C | A014-C-040 | Human | Colorectum | FAP | 7.18e-04 | -5.52e-01 | -0.1184 |
| 58489 | ABHD17C | A002-C-201 | Human | Colorectum | FAP | 1.66e-07 | -1.95e-01 | 0.0324 |
| 58489 | ABHD17C | A001-C-119 | Human | Colorectum | FAP | 1.03e-09 | -5.18e-01 | -0.1557 |
| 58489 | ABHD17C | A001-C-108 | Human | Colorectum | FAP | 1.79e-09 | -2.83e-01 | -0.0272 |
| 58489 | ABHD17C | A002-C-205 | Human | Colorectum | FAP | 6.82e-15 | -3.99e-01 | -0.1236 |
| 58489 | ABHD17C | A015-C-006 | Human | Colorectum | FAP | 5.68e-10 | -4.25e-01 | -0.0994 |
| 58489 | ABHD17C | A015-C-106 | Human | Colorectum | FAP | 4.13e-11 | -3.71e-01 | -0.0511 |
| 58489 | ABHD17C | A002-C-114 | Human | Colorectum | FAP | 3.41e-13 | -4.11e-01 | -0.1561 |
| 58489 | ABHD17C | A015-C-104 | Human | Colorectum | FAP | 6.19e-24 | -5.19e-01 | -0.1899 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
| GO:00421571 | Liver | HCC | lipoprotein metabolic process | 86/7958 | 135/18723 | 5.21e-07 | 8.38e-06 | 86 |
| GO:190382811 | Liver | HCC | negative regulation of cellular protein localization | 71/7958 | 117/18723 | 5.44e-05 | 5.12e-04 | 71 |
| GO:00360103 | Liver | HCC | protein localization to endosome | 19/7958 | 24/18723 | 2.80e-04 | 2.02e-03 | 19 |
| GO:00443802 | Liver | HCC | protein localization to cytoskeleton | 38/7958 | 58/18723 | 3.37e-04 | 2.36e-03 | 38 |
| GO:0042159 | Liver | HCC | lipoprotein catabolic process | 13/7958 | 15/18723 | 5.67e-04 | 3.61e-03 | 13 |
| GO:0098732 | Liver | HCC | macromolecule deacylation | 67/7958 | 116/18723 | 6.46e-04 | 3.99e-03 | 67 |
| GO:007269811 | Liver | HCC | protein localization to microtubule cytoskeleton | 35/7958 | 54/18723 | 7.73e-04 | 4.65e-03 | 35 |
| GO:00356011 | Liver | HCC | protein deacylation | 64/7958 | 112/18723 | 1.23e-03 | 6.83e-03 | 64 |
| GO:0098734 | Liver | HCC | macromolecule depalmitoylation | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
| GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
| GO:19038288 | Oral cavity | OSCC | negative regulation of cellular protein localization | 65/7305 | 117/18723 | 2.05e-04 | 1.36e-03 | 65 |
| GO:00443803 | Oral cavity | OSCC | protein localization to cytoskeleton | 33/7305 | 58/18723 | 4.32e-03 | 1.75e-02 | 33 |
| GO:00360105 | Oral cavity | OSCC | protein localization to endosome | 16/7305 | 24/18723 | 5.63e-03 | 2.17e-02 | 16 |
| GO:00421592 | Oral cavity | OSCC | lipoprotein catabolic process | 11/7305 | 15/18723 | 7.49e-03 | 2.75e-02 | 11 |
| GO:00726984 | Oral cavity | OSCC | protein localization to microtubule cytoskeleton | 30/7305 | 54/18723 | 9.99e-03 | 3.49e-02 | 30 |
| GO:0002084 | Oral cavity | OSCC | protein depalmitoylation | 8/7305 | 10/18723 | 1.03e-02 | 3.53e-02 | 8 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ABHD17C | SNV | Missense_Mutation | novel | c.649N>G | p.Thr217Ala | p.T217A | Q6PCB6 | protein_coding | deleterious(0.02) | benign(0.344) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ABHD17C | SNV | Missense_Mutation | c.718N>T | p.Arg240Cys | p.R240C | Q6PCB6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ABHD17C | SNV | Missense_Mutation | rs200549811 | c.973N>A | p.Glu325Lys | p.E325K | Q6PCB6 | protein_coding | deleterious(0.05) | benign(0.406) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ABHD17C | SNV | Missense_Mutation | c.874C>T | p.Pro292Ser | p.P292S | Q6PCB6 | protein_coding | tolerated(0.06) | probably_damaging(0.938) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ABHD17C | SNV | Missense_Mutation | rs200549811 | c.973G>A | p.Glu325Lys | p.E325K | Q6PCB6 | protein_coding | deleterious(0.05) | benign(0.406) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| ABHD17C | SNV | Missense_Mutation | novel | c.968C>A | p.Ser323Tyr | p.S323Y | Q6PCB6 | protein_coding | deleterious(0) | benign(0.364) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ABHD17C | SNV | Missense_Mutation | novel | c.367N>C | p.Met123Leu | p.M123L | Q6PCB6 | protein_coding | tolerated(0.26) | benign(0.007) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ABHD17C | SNV | Missense_Mutation | c.718N>T | p.Arg240Cys | p.R240C | Q6PCB6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ABHD17C | SNV | Missense_Mutation | novel | c.619C>T | p.Leu207Phe | p.L207F | Q6PCB6 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-EC-A1QX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
| ABHD17C | SNV | Missense_Mutation | novel | c.556N>C | p.Asp186His | p.D186H | Q6PCB6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |